1
). New drugs, and particularly specific inhibitors of HCV functions, are in preclinical and clinical development ( ).
2
Chronic HCV infection is also associated with altered lipid metabolism, resulting in low serum cholesterol, triglyceride and betalipoprotein levels ( , ). These abnormalities generally resolve after viral eradication ( , ). Hepatocellular steatosis, i.e. excessive 3 4 3 5
triglyceride accumulation within lipid droplets in the hepatocyte cytoplasm, is frequent in chronic hepatitis C ( ). Steatosis may be due to 6 metabolic disorders in patients with overweight, diabetes, dyslipidemia, and/or chronic alcohol consumption (metabolic steatosis).
Steatosis may also be directly related to virus replication (virus-induced steatosis), and both forms may be present together. Metabolic steatosis behaves in a similar way as in HCV non infected patients with non alcoholic fatty liver disease or alcoholic liver disease, and appears to influence the outcome of chronic liver disease and undermine the effectiveness of antiviral therapy ( , ). Virus-induced 7 8 steatosis is a cytopathic effect of HCV replication, but the precise underlying mechanisms are controversial. The influence of virus-induced steatosis on the outcome of liver disease and the response to therapy is unclear. Although HCV-induced steatosis is mostly seen in patients with HCV genotype 3a infection, in whom it correlates directly with the level of viral replication, cases have been reported with other genotypes ( , ). The reasons for these genotype differences are unclear. The level of virus expression required for excessive 9 10 triglyceride accumulation in hepatocytes might be lower in genotype 3 HCV infection.
Viral interaction with host lipid metabolism appears to be essential for the HCV cell cycle. Indeed, HCV replication occurs in association with endoplasmic reticulum (ER)-derived membranes and lipid droplets, and HCV core and nonstructural 5A (NS5A) protein addressing to lipid storage organelles plays an important role ( ). We recently showed that HCV core protein alters lipid droplet 11 -14 morphology ( ). Whether or not these effects play a role in hepatocellular steatosis is unclear. However, HCV protein expression has 15 been shown to induce steatosis in transgenic mice. In particular, we have previously shown that expression of the full HCV protein repertoire at physiological levels triggers hepatocellular steatosis in C57BL6 mice ( ). HCV protein expression thus appears sufficient to 16 induce hepatocellular steatosis, without the need for viral replication. HCV protein expression might: i) induce triglyceride de novo synthesis; ii) reduce cellular triglyceride excretion; iii) alter triglyceride oxidation; and/or (iv) increase triglyceride uptake from serum.
Sterol regulatory element binding proteins (SREBP) belong to the basic helix-loop-helix-leucine zipper family (bHLH/LZ) of transcription factors. They are synthesized as precursor proteins bound to the ER. The SREBP1c isoform is predominant in the liver and preferentially enhances the transcription of genes involved in fatty acid synthesis. Foreign protein synthesis inside host cells creates non specific stress that triggers the unfolded protein response (UPR). During the UPR, SREBP1c is matured by two successive cleavage steps and its transcription factor domain relocates to the nucleus, where it upregulates numerous genes involved in lipid synthesis and maturation. However, the effect of HCV proteins on these processes is largely unknown.
The goal of this study was to examine the mechanisms underlying HCV-induced lipid metabolic defects in a transgenic mouse model expressing the full HCV protein repertoire at levels corresponding to the human infection.
Experimental Procedures Animals
Animal housing was conducted in accordance with the Direction des Services V t rinaires, Minist re de l Agriculture of France, with ). The expression level of each studied gene was normalized to that of 18S ribosomal RNA by using the comparative C method. Table 1 T
XBP1 RT-PCR splicing assay
To analyze XBP1 mRNA splicing, 200 ng of cDNA was amplified with a pair of primers specific for the mouse XBP1 gene (sense: 5′ -GGCCTTGTGGTTGAGAACCAGGAG-3 ; antisense: 5 -GAATGCCCAAAAGGATATCAGACTC-3 ). The PCR conditions are
described in the Ron lab website ( ). PCR products were separated by http://saturn.med.nyu.edu/research/mp/ronlab/protocols.html electrophoresis on 2.5 agarose gels and visualized by ethidium bromide staining.
%

Preparation of cytoplasmic, microsomal and nuclear extracts and immunoblot analysis
Nuclear and cytoplasmic extracts were prepared from livers of wild-type and transgenic mice by using the NE-PER Nuclear and Cytoplasmic Extraction Reagent kit (Pierce Biotechnology, Rockford, Illinois), following the manufacturer s instructions. For microsomal ' extracts, mouse liver was homogenized in sucrose buffer (0.25 M sucrose, 10 mM Hepes, and 3 mM MgCl supplemented with protease 2 inhibitors, phenylmethylsulfonyl fluoride (1 mM), benzamidine (1 mM), DTT (1 mM), leupeptin (2 g/ml), and aprotinin (2 g/ml)). The 
Statistical analysis
Results are expressed as means standard error of the mean. The Fisher-Yates Terry or Mann-Whitney non parametric rank tests were ± used, as appropriate. Quantitative results are presented as box plots (median and 95th percentiles).
RESULTS
Expression of the HCV full-length open reading frame is associated with hepatocellular steatosis and reduced plasma triglyceride concentrations in transgenic mice
Steatosis was scored after hematoxylin-eosin and Oil-red-O staining of liver tissues. Steatosis was considered absent, mild, moderate and severe when respectively 0 , <30 , 30 60 and >60 of hepatocytes were positively stained. Although C57Bl6 mice have a natural MTP plays a key role in cotranslocational lipidation of apoB as it enters the ER lumen (thus preventing apoB degradation) and participates in the conversion of a precursor particle to VLDL by the addition of bulk triglycerides. As shown in , MTP activity Figure 2B was significantly lower in crude liver extracts from transgenic mice than from controls (p<0.05), confirming the impaired triglyceride excretion.
Lipogenesis is activated in mice transgenic for the HCV full-length open reading frame
In order to determine whether the lipogenic pathway is activated in HCV transgenic mice, hepatic transcriptional levels of genes coding for various enzymes involved in lipogenesis were compared with values in non transgenic controls. These genes included ATP citrate-lyase (ACL), which produces acetyl-CoA, the substrate of fatty acid synthase (FAS); acetyl-CoA carboxylase (ACC) and FAS, which catalyze fatty acid synthesis; malic enzyme (ME), which generates nicotinamide adenine dinucleotide phosphate (NADPH), a cofactor of FAS; and hepatic stearoyl-CoA desaturase 1 (SCD1), a protein involved in fatty acid processing. Transcript levels of all these enzymes were higher in transgenic mice than in controls, as measured by RTqPCR ( ). The difference was statistically Figure 3A ACC ME blotting of mouse liver extracts, was significantly higher in the liver of transgenic mice than in controls ( ). Together, these Figure 3B results suggest that the lipogenic pathway is activated in the liver of transgenic mice expressing the HCV full-length open reading frame. migrates to the nucleus, where it activates the transcription of major genes involved in fatty acid synthesis. Nuclear and microsomal protein fractions were purified from liver extracts of transgenic and non transgenic animals, and SREBP1c levels were assessed by western blotting. Lamin A/C and calnexin served as loading controls for the nuclei and microsomes, respectively. As shown in , figure 4A microsomal fractions from transgenic and non transgenic animals contained similar amounts of SREBP1c precursor. In contrast, mature cleaved SREBP1c was substantially more abundant in nuclear extracts from transgenic animals than from controls ( ), suggesting figure 4A that increased lipogenic enzyme transcription in HCV transgenic mice results from activation and nuclear translocation of SREBP1c. The expression of ChREBP, a transcription factor involved in the activation of glycolytic and lipogenic genes, was not modulated by the HCV transgene ( ). Figure 4A As shown in , the level of SREBP1c mRNA was slightly but not significantly higher in the liver of transgenic mice than in Figure 4B controls (fold increase compared to the mean control value: 1.3 0. proteins occurs at the maturation step rather than through gene activation. Similarly, the expression of ChREBP transcripts was not modulated by the HCV transgene ( ). Figure 4B 
SREBP1c is activated in mice transgenic
for the HCV full-length open reading frame Lipogenic enzymes are transcriptionally regulated by insulin and glucose through two transcription factors in the liver, namely
ER stress is not induced in mice transgenic for the HCV full-length open reading frame
Eukaryotic cells respond to the stress due to ER accumulation of misfolded, unfolded or foreign proteins, including viral proteins, by activating a signalling pathway known as the UPR that induces temporary translational inhibition followed by upregulation of ER chaperones. ATF6, inositol-requiring element 1 (IRE1) and PERK are ER-resident transmembrane proteins bound to GRP78 (BiP). In UPR conditions they are released from GRP78 and activated. As HCV proteins are synthesized on ER membranes and remain closely associated with ER-derived membranous webs, we examined whether HCV protein expression could trigger an unfolded protein response in HCV transgenic mice.
We first measured GRP78 mRNA levels. As shown in , no significant difference was found between transgenic and non Figure 5A transgenic mice. IRE1 release from GRP78 activates IRE1 RNase activity and initiates mRNA splicing of XBP1, thus generating a spliced mRNA encoding a transcription factor that activates UPR target genes. We screened total RNA extracts from transgenic and non transgenic livers for spliced XBP1 mRNA by means of RT-PCR and observed no modulation of XBP1 splicing by the HCV transgene ( ). Figure 5B PERK release from GRP78 induces PERK autophosphorylation and activation. Activated PERK (P-PERK) in turn phosphorylates eIF2 , thereby reducing mRNA translation initiation. We measured phosphorylated PERK and eIF2 by western blotting with specific α α antibodies, normalizing the results to the respective total amounts of the two proteins. As shown in , respectively, we Figures 5C and 5D found no difference in the levels of phosphorylated PERK and eIF2 between transgenic and non transgenic animals. Figure   , quantitative RT-PCR revealed no significant differences in EDEM or PDI mRNA levels between HCV transgenic and non transgenic 5E mice. C/EBP homologous protein (CHOP), also known as growth arrest-and DNA damage-inducible gene 153 (GADD153), is a component of the ER stress-mediated apoptosis pathway. TRB3 is induced by ER stress downstream of CHOP and was recently identified as a potential pro-apoptotic protein that can modulate the Akt/PKB-dependent signaling pathway. As shown in , CHOP and Figure 5F TRB3 expression levels did not differ between HCV transgenic and non transgenic mice, although there was a trend towards higher expression of CHOP transcripts in transgenic mice (p<0.06).
Protein disulfide isomerase (PDI) is another chaperone involved in the ER-associated degradation (ERAD) pathway. ER degradation-enhancing mannosidase-like proteins (EDEM) target UPR-inducing proteins and trigger their degradation. As shown in
Thus, none of the ER-stress markers tested here was expressed at significantly higher levels in HCV transgenic mice than in their wild-type counterparts. This suggests that SREBP1c proteolytic cleavage in transgenic mice expressing the HCV full-length open reading frame is independent of ER stress.
DISCUSSION
The mechanisms by which chronic HCV infection perturbs lipid metabolism are poorly understood. Intracellular virion production appears to use metabolic pathways involved in lipid metabolism ( ). Chronically HCV-infected patients often have low plasma 11 -15 cholesterol, triglyceride and betalipoprotein levels ( , ). In addition, virus-induced steatosis appears to be a direct cytopathic lesion 3 20 induced preferentially but not exclusively by genotype 3a HCV ( , ). A direct role of HCV is supported by the disappearance of these 21 22 abnormalities when the infection is cured by antiviral therapy, and by their reappearance after HCV reinfection of the donor liver in HCV-infected transplant recipients ( ). The precise role of HCV protein expression in these phenomena is unclear. 23 -25 The transgenic mice used here, which expresses the HCV full-length open reading frame, are a particularly relevant model for studying HCV protein-induced abnormalities, as all HCV proteins are produced at the same time at physiological levels, without virus production ( , ). We have previously reported that two lineages of transgenic mice expressing the HCV full-length open reading 16 26 -28 frame develop more frequent and more severe hepatocellular steatosis than their non transgenic littermates ( ). In the present study, 16 chronic expression of the entire panel of HCV proteins in mice receiving a normal diet was associated with lower plasma triglyceride levels and with mediovesicular steatosis preferentially located in the central vein area, exactly as in human HCV infection ( , ). 29 30 Several mutually non exclusive mechanisms could theoretically explain these observations. HCV protein expression could i) induce de triglyceride synthesis; ii) reduce cellular triglyceride secretion; iii) alter triglyceride degradation; and/or iv) increase triglyceride novo uptake from serum. Here we tested the first two hypotheses in transgenic mice expressing the HCV full-length open reading frame. Taken together, our results suggest that HCV protein expression induces triglyceride secretion independently of ER stress, and that it de novo also reduces triglyceride secretion in this model. FAS expression is mainly regulated at the transcriptional level by SREBP1. FAS-SREBP1 pathway alteration has been shown to be associated with steatosis ( ). We observed more mature SREBP1c in the nucleus of HCV transgenic mice than in non transgenic in vivo 33 controls, possibly explaining the enhanced FAS mRNA expression in the transgenic mice. This is in keeping with the recent report that SREBP1c proteolytic cleavage is induced by JFH1 infection in Huh-7 cells ( ). Likewise, a recent study comparing liver biopsy 34
specimens from HCV-infected and uninfected patients showed no difference in hepatic SREBP1c mRNA levels, but SREBP1c protein levels were not studied ( ). A role of HCV core, NS2 and NS4B proteins in SREBP1c proteolytic cleavage has been suggested, based on 35 transient over-expression of sequences derived from different HCV genotypes ( , , ). However, the viral protein(s) responsible for 34 36 37 SREBP1c activation remain to be identified. Finally, contrary to SREBP1c, ChREBP, another potent regulator of FAS expression at the transcriptional level ( ), was not involved in lipogenic pathway activation in our HCV transgenic mice. 38
SREBP-1c is a potent negative regulator of MTP expression ( ). HCV protein activation of SREBP1c could thus down-regulate 39
MTP activity, thereby explaining the decreased MTP activity that we observed in transgenic mice expressing the HCV full-length open reading frame. Reduced MTP activity could in turn be responsible for the defective VLDL secretion which, in combination with increased triglyceride synthesis, participates in hepatocyte triglyceride accumulation. It is noteworthy in this respect that reduced plasma MTP activity has also been reported in HCV-infected patients ( ). Transgenic mice overexpressing HCV core protein also show reduced MTP 40 activity ( ), but MTP mRNA levels and activity are also reduced in the HCV subgenomic replicon model, which lacks HCV core protein 17
Before concluding that triglyceride synthesis mediated by enhanced FAS expression results from direct SREBP1c activation de novo by HCV protein(s), it was important to eliminate a potential role of viral protein-induced ER stress. The unfolded protein response is triggered by the accumulation of unfolded, misfolded or foreign proteins within the ER. Thus, HCV protein expression and accumulation in transgenic hepatocytes could trigger ER stress, triggering non specific SREBP1c cleavage and activation. We therefore studied the three principal ER stress pathways, driven by PERK, ATF6 and IRE1, under the control of GRP78 (or BiP). None was found to be activated in transgenic hepatocytes: GRP78 expression, PERK and eiF2 phosphorylation, and XBP-1 mRNA splicing were similar in HCV transgenic α and non transgenic livers. These findings appear to conflict with previous reports. Indeed, ectopic expression of HCV envelope glycoproteins E1 and E2 has been reported to increase GRP78 expression ( ). However, in these experiments, a large proportion of E1 42
and E2 proteins were trapped in the ER as aggregates, a phenomenon that does not occur during natural infection. Likewise, GRP78
expression has been reported to be induced in the replicon system, a replicative model based on Huh-7 cells. However, GRP78 induction was three times higher than in the same cells expressing HCV nonstructural proteins in the absence of replication, and HCV replication contributed to stimulating ER chaperone expression ( ). Finally, the E2 envelope glycoprotein has been reported to bind PERK as a 43 pseudosubstrate, to inhibit its autophosphorylation, and to sequester it from its substrate eIF2 , potentially masking downstream ER stress α events ( ). However, high E2 expression was required for this inhibition to occur. In addition, The FL-N/35 lineage is characterized by 44 its very low level of HCV protein expression. Indeed, we were only able to demonstrate transgene expression within the mouse liver by using very sensitive immunochemical methods ( ). Therefore, our findings conclusively show that HCV protein expression stimulates 26 triglyceride synthesis independently of non specific ER stress activation.
In conclusion, transgenic mice expressing the HCV full-length polyprotein at low, physiological levels, have decreased plasma triglyceride levels and develop hepatocellular steatosis in the same way as HCV-infected patients. In these transgenic mice, de novo triglyceride synthesis is induced by direct SREBP1c activation by one or several HCV proteins through induction of the lipogenic pathway, independently of ER stress, while triglyceride secretion is simultaneously reduced. The HCV protein(s) responsible for these perturbations of lipid metabolism remain to be identified, along with the underlying molecular mechanisms.
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(B)
Box-and-whisker graphs are used; the line in the middle is the median, the box extends from the 25th to the 75th percentile, and the whiskers extend to the lowest and highest values. Values in WT and HCV-tg mice were compared with the Mann and Whitney test.
Fig. 3
Gene expression of ATP citrate-lyase (ACL), acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), malic enzyme (ME) and hepatic (A) stearoyl-CoA desaturase 1 (SCD1), assessed by RT-qPCR in the livers of wild-type mice (WT) and HCV transgenic (HCV-tg) littermates (all males, 8 to 9 months old). The results were normalized to the mean expression level in WT liver.
Fatty acid synthase (FAS) protein (B) expression, assessed by western blotting. The left-hand panel shows a representative blot. Variations between samples were normalized on the basis of GAPDH expression. The results were normalized to the mean expression level in WT liver. Box-and-whisker graphs are used. Values in WT and HCV-tg mice were compared with the Mann and Whitney test.
Fig. 4
Western blot analysis showing cleaved SREBP1c and nuclear ChREBP expression in wild-type mice (WT) and HCV transgenic (A) littermates (HCV-tg); liver cell nuclear extracts are shown at the top, and liver cell microsome extracts at the bottom. Lamin A/C and actin, respectively, were used as references.
SREBP1c and ChREBP mRNA levels assessed by RT-qPCR in the liver of WT and HCV-tg mice.
(B)
The results were normalized to the mean expression level in WT liver. Box-and-whisker graphs are used. Values in WT and HCV-tg mice were compared with the Mann and Whitney test.
Fig. 5
GRP78 mRNA levels assessed by RT-qPCR in the liver of wild-type mice (WT) and HCV transgenic littermates (HCV-tg). The results (A) were normalized to the mean expression level in WT liver. Box-and-whisker graphs are used. Values in WT and HCV-tg mice were compared with the Mann and Whitney test.
Unspliced and spliced XBP1 mRNA transcripts in liver RNA extracts from WT and HCV-tg mice, as 
